Cargando…

A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee.

Twelve patients were treated with didox, a new ribonucleotide reductase inhibitor, by 36 h infusion. The maximum tolerated dose was 6 g m-2, above which dose-limiting hepatic toxicity was observed. Patient tolerance was significantly better using the 36 h infusion compared to patients receiving the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carmichael, J., Cantwell, B. M., Mannix, K. A., Veale, D., Elford, H. L., Blackie, R., Kerr, D. J., Kaye, S. B., Harris, A. L.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1990
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971305/ https://www.ncbi.nlm.nih.gov/pubmed/2183873

Ejemplares similares

A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.
por: Veale, D., et al.
Publicado: (1988)

Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
por: Rubens, R. D., et al.
Publicado: (1991)

The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML
por: Cook, Guerry J., et al.
Publicado: (2014)

Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox
por: Inayat, Mohammed S, et al.
Publicado: (2010)

A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
por: Smith, D. B., et al.
Publicado: (1988)

The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells
por: Asperti, Michela, et al.
Publicado: (2019)

Phase I and pharmacokinetic study of D-verapamil and doxorubicin.
por: Bissett, D., et al.
Publicado: (1991)

The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines
por: Abdel-Latif, Ghada A., et al.
Publicado: (2015)

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.
por: Stein, R. C., et al.
Publicado: (1990)

A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
por: Bleehen, N. M., et al.
Publicado: (1994)

Test Beam Campaigns for the CMS Phase I Upgrade Pixel Readout Chip
por: Spannagel, Simon
Publicado: (2014)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity
por: Khaleel, Sahar A., et al.
Publicado: (2016)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
por: Foster, B. J., et al.
Publicado: (1993)

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.
por: Savage, P., et al.
Publicado: (1996)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
por: Vermunt, Marit, et al.
Publicado: (2021)

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days
por: Bilenker, J H, et al.
Publicado: (2004)

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia
por: Schimmer, Aaron D., et al.
Publicado: (2014)

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
por: Fumoleau, Pierre, et al.
Publicado: (2013)

The Campaign of the London Medical Committee
Publicado: (1913)

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
por: Diaz-Padilla, I, et al.
Publicado: (2012)

Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee.
por: Kaye, S. B., et al.
Publicado: (1992)

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours
por: de Jonge, M J A, et al.
Publicado: (2004)

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
por: Rixe, Olivier, et al.
Publicado: (2015)

Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.
por: Millward, M. J., et al.
Publicado: (1991)

Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
por: Foster, B. J., et al.
Publicado: (1993)

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
por: Rasschaert, M, et al.
Publicado: (2007)

Experimental designs for phase I and phase I/II dose-finding studies
por: O'quigley, J, et al.
Publicado: (2006)

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
por: Chen, X, et al.
Publicado: (2003)

Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial
por: Rouphael, Nadine G., et al.
Publicado: (2021)

Phase I and Phase II CMS upgrade
por: Heister, A
Publicado: (2014)

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
por: Clamp, A R, et al.
Publicado: (2003)

Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK
por: Newell, D R, et al.
Publicado: (2003)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies
por: Emanuel, Ezekiel J, et al.
Publicado: (2015)

Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016)

Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
por: Bissett, D., et al.
Publicado: (1995)

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection
por: Leal, Lorna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_30inppcsbv9lc4go0gm7erdnkf